LENZ Therapeutics Valuation
| LENZ Stock | 25.48 0.30 1.19% |
At this time, the firm appears to be undervalued. LENZ Therapeutics secures a last-minute Real Value of USD28.58 per share. The latest price of the firm is USD25.48. Our model forecasts the value of LENZ Therapeutics from evaluating the firm fundamentals such as current valuation of 406.07 M, and Return On Equity of -1.58 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting LENZ Therapeutics' valuation include:
Undervalued
Today
Please note that LENZ Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of LENZ Therapeutics is based on 3 months time horizon. Increasing LENZ Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since LENZ Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of LENZ Stock. However, LENZ Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.48 | Real 28.58 | Target 33.8 | Hype 25.71 | Naive 28.53 |
The intrinsic value of LENZ Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence LENZ Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of LENZ Therapeutics helps investors to forecast how LENZ stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of LENZ Therapeutics more accurately as focusing exclusively on LENZ Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use LENZ Therapeutics' intrinsic value based on its ongoing forecasts of LENZ Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against LENZ Therapeutics' closest peers.
LENZ Therapeutics Cash |
|
LENZ Valuation Trend
Analysing the historical paterns of LENZ Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of LENZ Therapeutics over time and is usually enough for investors to make rational market timing decisions.
LENZ Therapeutics Total Value Analysis
LENZ Therapeutics is now estimated to have valuation of 406.07 M with market capitalization of 600.49 M, debt of 362 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the LENZ Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
406.07 M | 600.49 M | 362 K |
LENZ Therapeutics Asset Utilization
One of the ways to look at asset utilization of LENZ is to check how much profit was generated for every dollar of assets it reports. LENZ Therapeutics secures a negative usage of assets of -0.77 %, losing USD0.007717 for each dollar of assets held by the firm. Ineffective asset utilization conveys that the company is being less capable with each dollar of assets it secures. Strictly speaking, asset utilization of LENZ Therapeutics shows how unsuccessful it operates for each dollar spent on its assets.LENZ Therapeutics Ownership Allocation
LENZ Therapeutics maintains a total of 27.47 Million outstanding shares. The majority of LENZ Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in LENZ Therapeutics to benefit from reduced commissions. Thus, institutional holders are subject to a different set of regulations than regular investors in LENZ Therapeutics. Please pay attention to any change in the institutional holdings of LENZ Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.LENZ Therapeutics Profitability Analysis
Net Loss for the year was (124.65 M) with profit before overhead, payroll, taxes, and interest of 0.LENZ Therapeutics Past Distributions to stockholders
About LENZ Therapeutics Valuation
Our relative valuation model uses a comparative analysis of LENZ Therapeutics. We calculate exposure to LENZ Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of LENZ Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2.8 M | -2.6 M | |
| Pretax Profit Margin | (6.06) | (6.37) | |
| Operating Profit Margin | (6.34) | (6.66) | |
| Net Loss | (6.06) | (6.37) | |
| Gross Profit Margin | 0.40 | 0.35 |
A single share of LENZ Therapeutics represents a small ownership stake in the entity. As a stockholder of LENZ, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
LENZ Therapeutics Dividends Analysis For Valuation
Please note that LENZ Therapeutics has scaled down on payment of dividends at this time. Retained Earnings is likely to rise to about (313.8 M) in 2025. Earnings Yield is likely to rise to -1.35 in 2025
There are various types of dividends LENZ Therapeutics can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of LENZ shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from LENZ Therapeutics directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When LENZ pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of LENZ Therapeutics by the value of the dividends paid out.
LENZ Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 8.1 M |
LENZ Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of LENZ Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value LENZ we look at many different elements of the entity such as LENZ's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as LENZ Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use LENZ Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes LENZ Therapeutics' worth.Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.